News | July 28, 2022
Biocon Q1FY23 consolidated PAT falls QoQ at Rs. 144.4 Cr
Biocon has reported total income of Rs. 2217.4 crores during the period ended June 30, 2022.
Biocon has reported total income of Rs. 2217.4 crores during the period ended June 30, 2022.
This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
Merck’s first microbiology application and training lab in India
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
ExoBrite antibody conjugates are validated and optimized for bright and specific detection of exosome markers
Cellutions BioStorage is a comprehensive biomaterial storage and logistics company with a vision to leverage advanced technologies to serve biopharmaceutical companies
Advancing to IND-enabling studies with multiple drug candidates
Syngene's collaboration with Zoetis started in 2011
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
Subscribe To Our Newsletter & Stay Updated
